Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer

被引：0
|
作者：
Natsuko Hori
Satoru Iwasa
Hironobu Hashimoto
Takako Yanai
Ken Kato
Tetsuya Hamaguchi
Yasuhide Yamada
Kouji Murakoshi
Nobuaki Yokote
Hiroshi Yamamoto
Yasuhiro Shimada
机构：
[1] National Cancer Center Hospital,Division of Pharmacy
[2] National Cancer Center Hospital,Gastrointestinal Oncology Division
来源：
International Journal of Clinical Oncology | 2013年 / 18卷
关键词：
Bevacizumab; Colorectal cancer; FOLFOX; Contraindications;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：435 / 438
页数：3
相关论文
共 50 条
  • [1] Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer
    Hori, Natsuko
    Iwasa, Satoru
    Hashimoto, Hironobu
    Yanai, Takako
    Kato, Ken
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Murakoshi, Kouji
    Yokote, Nobuaki
    Yamamoto, Hiroshi
    Shimada, Yasuhiro
    [J]. INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2013, 18 (03) : 435 - 438
  • [2] FOLFOX plus cetuximab in first-line therapy of advanced colorectal cancer
    Ehrenberg, Roland
    Halama, Niels
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [3] Stop and Go FOLFOX plus Bevacizumab Chemotherapy in the First-Line Treatment of Metastatic Colorectal Cancer
    Vaidyanathan, Gayatri
    Groman, Adrienne
    Wilding, Gregory
    Fakih, Marwan G.
    [J]. ONCOLOGY, 2010, 79 (1-2) : 67 - 71
  • [4] Phase II trial of autophagy inhibition using hydroxychloroquine (HCQ) with FOLFOX/bevacizumab in the first-line treatment of advanced colorectal cancer
    Loaiza-Bonilla, Arturo
    O'Hara, Mark H.
    Redlinger, Maryann
    Damjanov, Nevena
    Teitelbaum, Ursina R.
    Vasilevskaya, Irina
    Rosen, Mark Alan
    Heitjan, Daniel F.
    Amaravadi, Ravi K.
    O'Dwyer, Peter J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Bevacizumab plus FOLFOX7 as first line treatment in patients with advanced colorectal cancer
    Oukkal, M.
    Kara, F.
    Difi, S.
    Bouzidi, D.
    Bentabak, K.
    Graba, A.
    Smail, N.
    Kaci, N. Ait
    Ahmed, R. Baba
    Bouzid, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] The efficiency of FOLFOX and XELOX application as a first-line chemotherapy of the advanced colorectal cancer patients
    Zeynalov, R.
    Musayev, I
    Gasanzadeh, J.
    Ahadova, N.
    Dadasheva, N.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 81 - 81
  • [7] A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer
    Xiong, Jian Ping
    Zhang, Ling
    Zhong, Lu Xing
    Qiu, Feng
    Xu, Jun
    Tao, Qing Song
    Xiang, Xiao Jun
    Yu, Feng
    Tang, Xiao Mei
    [J]. ANTI-CANCER DRUGS, 2007, 18 (09) : 1103 - 1107
  • [8] Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Ueno, Masashi
    Yamaguchi, Toshiharu
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (04) : 322 - 329
  • [9] Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with, metastastic colorectal cancer
    Meyerhardt, J. A.
    Stuart, K.
    Fuchs, C. S.
    Zhu, A. X.
    Earle, C. C.
    Bhargava, P.
    Blaszkowsky, L.
    Enzinger, P.
    Mayer, R. J.
    Battu, S.
    Lawrence, C.
    Ryan, D. P.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (07) : 1185 - 1189
  • [10] Bevacizumab in the First-line Treatment of advanced Ovarian Cancer
    Mallmann, Michael R.
    Alakus, Hakan
    Mallmann, Peter
    Bruns, Christiane
    [J]. ONKOLOGE, 2019, 25 (11): : 1020 - 1021
12345